NEW YORK (GenomeWeb News) – KineMed said today that it has received a $225,000 Phase I Small Business Innovation Research contract from the National Heart, Lung, and Blood Institute for research into biomarkers for the early detection of myocardial fibrosis.

The contract is focused specifically on developing non-invasive methods to detect and monitor myocardial fibrosis in vivo. In previous work, KineMed has identified via its Dynamic Proteomics technology blood proteins that may potentially serve as markers of the fibrotic process in remodeling heart tissue.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.